米诺环素单用及联合利福平抗金黄色葡萄球菌的体外药效学研究
该研究采用体外药代动力学模型,建立米诺环素单用及联合利福平对金黄色葡萄球菌的fAUC/MIC靶值。米诺环素24小时静态效应和-1 log下降的fAUC/MIC分别为12.5±7.1和23.3±12.4,48和72小时靶值更高。模拟7-10天人体给药显示米诺环素单药可降低菌量1-3 log且无耐药,联合利福平虽进一步降低菌量但出现利福平耐药。
要点
- 米诺环素抗金葡菌fAUC/MIC靶值12-36适用。
- 联合利福平降低菌量但出现利福平耐药。
- 米诺环素单药未见耐药出现。
核心结论
- 米诺环素fAUC/MIC靶值12-36适用于金黄色葡萄球菌。
- 联合利福平降低细菌负荷但导致利福平耐药出现。
- 米诺环素单用未见耐药出现。
研究设计与样本
- 采用体外药代动力学模型,暴露范围设计建立米诺环素单用及联合利福平的fAUC/MIC靶值。
- 模拟米诺环素及联合利福平7-10天人体给药方案。
主要发现
- 米诺环素24小时静态效应和-1 log下降的fAUC/MIC分别为12.5±7.1和23.3±12.4。
- 48和72小时静态及-1 log下降的fAUC/MIC靶值更高。
- 模拟利福平300 mg q12h游离药物暴露降低24小时米诺环素fAUC/MIC。
- 7-10天模拟显示米诺环素标准人体剂量下活菌计数降低1-3 log且种群谱无变化。
- 联合利福平菌量降低更显著但出现利福平耐药,米诺环素无耐药。
关键数值与推荐
- 米诺环素24小时静态效应fAUC/MIC为12.5±7.1。
- 米诺环素24小时-1 log下降fAUC/MIC为23.3±12.4。
- 米诺环素fAUC/MIC靶值12-36适用于金黄色葡萄球菌。
临床怎么用
- 米诺环素治疗MRSA感染可参考fAUC/MIC 12-36作为药效学靶值。
- 联合利福平虽增强杀菌但需警惕利福平耐药出现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tetracyclines are widely used as oral therapy of MRSA infection, however, the pharmacodynamic underpinning is absent. OBJECTIVES: We employed an in vitro pharmacokinetic model to study the pharmacodynamics of minocycline alone and in combination with rifampicin. METHODS: An exposure-ranging design was used to establish fAUC/MIC targets for static, -1 log drop and -2 log drop effects against Staphylococcus aureus for minocycline and in combination with rifampicin. We then simulated 7-10 day human dosing of minocycline and the combination. RESULTS: The minocycline fAUC/MIC for 24 h static effect and -1 log drop in bacterial load were 12.5 ± 7.1 and 23.3 ± 12.4. fAUC/MIC targets for static and -1 log drop were greater at 48 and 72 h. The addition of simulated free rifampicin associated with dosing 300 mg q12h reduced the 24 h minocycline fAUC/MICs. Simulations performed over 7-10 days exposure indicated that for minocycline standard human doses there was a 1-3 log reduction in viable count and no changes in population profiles. Addition of rifampicin resulted in larger reductions in staphylococcal load but emergence of resistance to rifampicin. There was no resistance to minocycline. CONCLUSIONS: An fAUC/MIC minocycline target of 12-36 is appropriate for S. aureus. Addition of rifampicin decreases bacterial load but results in emergence of resistance to rifampicin. Unusually, there was no emergence of resistance to minocycline.
引用
- Noel AR, Attwood M, Bowker KE, et al. The pharmacodynamics of minocycline alone and in combination with rifampicin against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. J Antimicrob Chemother. 2021. PMID: 33975336. doi:10.1093/jac/dkab112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。